Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies
索拉非尼剂量增加并非总是会导致晚期恶性肿瘤患者血压升高(即使血压正常)。
期刊:Clinical Pharmacology & Therapeutics
影响因子:5.5
doi:10.1038/clpt.2014.63
Karovic, S; Wen, Y; Karrison, T G; Bakris, G L; Levine, M R; House, L K; Wu, K; Thomeas, V; Rudek, M A; Wright, J J; Cohen, E E W; Fleming, G F; Ratain, M J; Maitland, M L